XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Note 2 - Significant Accounting Policies (Details Textual)
 3 Months Ended 6 Months Ended 9 Months Ended
Apr. 22, 2024
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Sep. 22, 2023
shares
Amortization of above and below Market Leases   $ 1,244     $ 3,731                
Deferred Costs   1,600,000           $ 1,600,000   $ 1,600,000   $ 1,700,000  
Operating Lease, Initial Direct Cost Expense, over Term   125,302     123,408         369,401 $ 351,559    
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents   7,199,448           7,199,448   7,199,448   6,510,428  
Restricted Cash   3,500,000           3,500,000   3,500,000   3,700,000  
Cash, Uninsured Amount   1,300,000           1,300,000   1,300,000   700,000  
Unamortized Deferred Stock Costs   0           0   0   5,000  
Impairment of Real Estate   697,146     0         893,939 0    
Proceeds from Sale of Real Estate                   22,300,000      
Gain (Loss) on Sale of Properties                   3,200,000      
Marketable Securities   0           0   0   45,149  
Marketable Securities, Cost Basis                       40,315  
Equity Securities, FV-NI   481,219           481,219   481,219   18,318,521  
Accounts Payable and Accrued Liabilities   3,497,588           3,497,588   3,497,588   4,770,845  
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition   347,021 $ 343,108 $ 317,077 270,564 $ 228,657 $ 232,106            
Net Cash Provided by (Used in) Operating Activities                   (1,040,830) (356,973)    
Net Cash Provided by (Used in) Investing Activities                   10,664,729 129,013,895    
Capital Expenditures Incurred but Not yet Paid               1,000,000          
Revision of Prior Period, Error Correction, Adjustment [Member]                          
Accounts Payable and Accrued Liabilities                       (21,189)  
Additional Paid in Capital                       21,189  
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition       317,077 $ 270,564 $ 228,657 $ 232,106            
Previously Reported [Member]                          
Net Cash Provided by (Used in) Operating Activities                     488,137    
Net Cash Provided by (Used in) Investing Activities                     128,168,785    
Revision of Prior Period, Adjustment [Member]                          
Net Cash Provided by (Used in) Operating Activities                     (850,918)    
Net Cash Provided by (Used in) Investing Activities                     $ 850,918    
Capital Expenditures Incurred but Not yet Paid       $ 48,207         $ 204,054        
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 540,000                       754,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 3.12                        
Warrants and Rights Outstanding, Term (Year) 2 years                        
Warrant or Right, Exercisable Period (Year) 1 year                        
Warrants and Rights Outstanding $ 891,000                        
Conduit Pharmaceuticals Inc [Member]                          
Lock-up Agreement, Shares (in shares) | shares 2,700,000                        
Investment Owned, Balance, Shares (in shares) | shares 4,015,250                        
Equity Securities, FV-NI   500,000           500,000   500,000   18,300,000  
Investment Owned, Fair Value   $ 500,000           $ 500,000   $ 500,000      
Fair Value, Inputs, Level 1 [Member]                          
Marketable Securities                       45,149  
Discontinued Operations, Disposed of by Sale [Member]                          
Number of Real Estate Properties   46     15     46   46 15    
Gain (Loss) on Sale of Properties                   $ 3,200,000 $ 2,300,000    
Model Home [Member]                          
Impairment of Real Estate   $ 200,000               $ 200,000      
Number of Real Estate Properties   19     25     19   19 25    
Dakota Center [Member]                          
Impairment of Real Estate   $ 700,000               $ 700,000      
Model Home Properties [Member]                          
Impairment of Real Estate   41,656               238,449      
Finite-lived Intangibles, Other Than Lease Intangibles [Member]                          
Amortization of Intangible Assets   $ 4,382     $ 13,145         $ 4,382 $ 13,145    
Minimum [Member]                          
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   1 year           1 year   1 year      
Leasehold Improvements [Member] | Maximum [Member]                          
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   10 years           10 years   10 years      
Furniture and Fixtures [Member] | Maximum [Member]                          
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   5 years           5 years   5 years      
Furniture and Fixtures [Member] | Minimum [Member]                          
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   1 year           1 year   1 year      
Building and Tenant Improvements [Member]                          
Accounts Payable         $ 850,918           $ 850,918 $ 295,567  
Murphy Canyon Acquisition Sponsor, LLC (SPAC) [Member]                          
Subsidiary, Ownership Percentage, Parent                         65.00%